FOLH1 and neuroendocrine neoplasm: Other tracers visualize expression of receptors that can be targeted by drugs (e.g. 18F-fluoroestradiol (FES-) PET 78, 79, human epidermal growth factor receptor 2 (HER2-) PET or SPECT 80), demonstrate suitability for targeted therapy (e.g. response prediction to tyrosine kinase inhibitors in non-small cell lung cancer 76, 81), or image tumour specific markers (e.g. prostate specific membrane antigen (PSMA-) PET 82, 83 and radiolabelled somatostatin analogues for neuroendocrine tumours 84, 85).